Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Urination Disorders
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urologic Diseases » Urination Disorders
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urologic Diseases » Urination Disorders
Description
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE. MeSH
Hierarchy View
Subtype Terms (9)
Proteinuria
82 drugs (65 approved, 17 experimental)
Urinary Incontinence
57 drugs (30 approved, 27 experimental)
Urinary Retention
17 drugs (14 approved, 3 experimental)
Phase 4 Indicated Drugs (16)
Phase 1 Indicated Drugs (7)
Other Experimental Indicated Drugs (11)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (3)
Organization Involved with Phase 1 Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
